Applied Therapeutics (NASDAQ:APLT) stock is on the rise Wednesday after the clinical-stage biopharmaceutical company got an update from the Food and Drug Administration (FDA). The FDA has accepted the company’s New Drug Application (NDA) for govorestat as a treatment for Classic Galactosemia. It was also granted Priority Review status with a target action date of Aug. 28, 2024. To go along with this, the FDA is planning an advisory committee meeting to review the NDA for govorestat. Investors will note that ...